Contact

Corporate HQ, R&D and Vaccine Manufacturing

Agenus Inc

3 Forbes Road
Lexington, MA 02421-7305

T: 781.674.4400

F: 781.674.4200

Antibody Manufacturing

Agenus West LLC

793 Heinz Ave.
Berkeley, CA 94710

T: 781.674.4400

F: 781.674.4200

Early Discovery and Development

Agenus UK Limited

315 Science Park
Milton Road
Cambridge, UK CB4 0WG

T: 781.674.4400

F: 781.674.4200

Email Us

Name*
First Last
Title
Company
Email*
Enter Email Confirm Email
Phone
Mailing address*
Street Address Address Line 2 City State / Province / Region ZIP / Postal Code
Email us
Subject*
Message*
Email*
Name
This field is for validation purposes and should be left unchanged.

Partner with Us

In-Licensing

To build near-term commercial opportunities, Agenus seeks to in-license immuno-oncology assets that complement and offer compelling combination therapy opportunities with our current portfolio, from preclinical to late stage development. We are also interested in platform technologies with the potential to enhance our capabilities to generate revenues from multiple product and combination product opportunities. For further information, please contact Business Development through our contact form below.

Out-Licensing

Agenus is interested in additional partnerships that leverage our portfolio of products and platform technologies including our checkpoint modulators, vaccine candidates, and QS-21 Stimulon^® adjuvant. The targeted partnerships are designed to accelerate timelines of development as well as significantly enhance the market potential of our portfolio of products. We are also interested in deploying our antibody discovery platforms towards the development of novel therapeutic antibodies with applications beyond immuno-oncology with selected partners. For further information, please contact Business Development through our contact form below.

Company*
Name*
First Last
Email*
Enter Email Confirm Email
Submit a non-confidential request
Attachment
Optionally, attach a file with your request.
Name
This field is for validation purposes and should be left unchanged.

Compassionate Access Policy

Agenus is committed to developing therapies for patients with cancer. Our goal is to provide access to our investigational therapies at the appropriate time and in the correct manner for patients. You can find information on access here: Agenus Compassionate Use Policy.

Get In Touch

Call us with questions or submit a partner request.

Call Us: 781.674.4400 Submit a Request

Contact

Email us

In-Licensing

Out-Licensing